Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In 1994, the landmark Scandinavian Simvastatin Survival Study (“4S”) demonstrated for the first time that a new class of drug could reduce morbidity and mortality in patients with ischaemic heart disease, leading to a major change in the way the condition is managed.1 The past 18 years have seen the introduction of other statins, a plethora of national and international guidance on their use and a significant increase in the numbers of patients taking such drugs. And for much of this time the choice of statin has been keenly debated by clinicians and commissioners of health …